NICE National Institute for Health and Care Excellence

NICE guidance

Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)

Technology appraisal guidance
Published: 31 March 2021

www.nice.org.uk/guidance/ta686

Contents

Advice 3

Information 3

Advice

NICE is unable to make a recommendation about the use in the NHS of blinatumomab for treating Philadelphia-chromosome-positive relapsed or refractory acute lymphoblastic leukaemia. This is because Amgen UK has confirmed that it does not intend to make an evidence submission for the appraisal. Amgen UK considers that there is unlikely to be enough evidence that the technology is a cost-effective use of NHS resources for this population.

Information

If NHS organisations wish to consider blinatumomab for this indication, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-4070-7

Accreditation